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Abstract. Stunting, defined as height-for-age Z score equal to or lower than −2, is associated with increased child-
hood mortality, cognitive impairment, and chronic diseases. The aim of the study was to investigate the relationship
between linear growth, intestinal damage, and systemic inflammation in infants at risk of stunting. We followed up 78
infants aged 5–12 months living in rural areas of Peru for 6 months. Blood samples for biomarkers of intestinal damage
(intestinal fatty-acid–binding protein [I-FABP] and zonulin) and systemic inflammation (interleukin-1β, interleukin-6, tumor
necrosis factorα [TNF-α], solubleCD14, and lipopolysaccharide-binding protein [LBP]) and fecal samples formicrobiome
analysis were collected at baseline and closure of the study. The children’s growth and health status were monitored
through biweekly home visits by trained staff. Twenty-one percent of the children became stunted: compared with non-
stunted children, they had worse nutritional parameters and higher levels of serum I-FABP at baseline. The likelihood of
becoming stunted was strongly associated with an increase in sCD14 over time; LBP and TNF-α showed a trend toward
increase in stunted children but not in controls. The fecal microbiota composition of stunted children had an increased
beta diversity compared with that of healthy controls throughout the study. The relative abundance of Ruminococcus 1
and 2, Clostridium sensu stricto, and Collinsella increased in children becoming stunted but not in controls, whereas
Providencia abundance decreased. In conclusion, stunting in our population was preceded by an increase in markers of
enterocyte turnover and differences in the fecal microbiota and was associated with increasing levels of systemic
inflammation markers.
INTRODUCTION
Worldwide, 155 million children are stunted, meaning that
their height or length is less than two SDs from the median
value expected for age and gender.1 Childhood stunting is
associated with increased childhood mortality, cognitive im-
pairment, andahigher riskof chronicdiseases later in life2 and,
therefore, represents a serious public health concern. The
suboptimal linear growth may be in part explained by a
chronically inadequate diet. In fact, most stunted individuals
come from food-insecure households.3 However, interven-
tions solely focused on improving nutrition fail to restore their
normal trajectory of growth.4Analternative or additional cause
may be chronic systemic inflammation as suggested by mul-
tiple studies showing that stunted children have an increased
level of blood inflammation markers.5–8 The origin of this in-
flammatory status could be a sustained, aberrant activation of
the mucosal immune system. Indeed, there is an established
association between stunting and the environmental enteric
disorder (EED), a small-intestine enteropathy highly prevalent
in low-resource countries and characterized by mucosal in-
flammation, small intestine villi flattening, and increased in-
testinal permeability.9–14 The triggers for this disorder are
probably inadequate diet, continuous exposure to environ-
mental contaminants, and/or an alteration of the normal
commensal flora.
Here, we present the results of a study investigating the
relationship between linear growth, markers of intestinal
damage, and systemic inflammation among infants in rural
Peru.
METHODS
Study design and description of the setting. The study
was approved by the Institutional Review Boards of the Uni-
versity of Texas (UT) Health Science Center at Houston, UT
Medical Branch in Galveston, Texas, and the Universidad
Peruana Cayetano Heredia in Lima, Peru. The Ministry of
Health Authorities of Moyobamba and Urubamba endorsed
the study.
This was a pilot prospective study. Infants from two com-
munities of rural Peru were enrolled and followed up for
6 months between December 2014 and May 2015, during the
summer/raining season. The research siteswere situated in the
Urubamba district of the Cusco region, in the Peruvian Andes
highlands, and in theMoyobamba district of SanMartin region,
in the Northeastern part of the Peruvian Amazon. According to
a 2014 survey (Instituto Nacional de Estadistica e Informatica,
2015), theprevalenceofstuntingamongchildrenaged less than
5 years in the two regions was 18% and 16%, respectively.
Subjects. Infants aged 5–12 months were identified using
local health centers’ databases. Their families were home-
visited by the research team, and written consent was
obtained from both parents. Children were eligible if they had
no history of prematurity, severe chronic illness, or previously
diagnosed failure to thrive; they had a length-for-age Z (LAZ)
score greater than −2 at enrollment; and their families agreed
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on close follow-up. Patients could withdraw from the study at
any time.
At the end of the study, we classified children as “stunted” if
their last LAZ score at the end of the follow-up was equal to or
lower than −2, whereas we defined “controls” as children who
had a last LAZ score above −2.
Household characteristics and nutritional surveys.
Caregivers were interviewed on enrollment using a structured
questionnaire to gather information regarding family compo-
sition and household characteristics. Nutritional surveys were
conducted at the beginning and closure of the study and
aimed at collecting information regarding duration and pattern
of breastfeeding and diet characteristics in the first 2 years of
life. A diet diversity score (DDS) was calculated for each child
as per international guidelines.15
Growth monitoring. Participants’ weight and length were
measuredat enrollment andmonthly thereafter by trained staff
using a calibrated hanging scale and a length board. Weight-
for-age Z (WAZ), LAZ, and weight-for-height Z scores were
calculated using WHO Anthro software, version 3.2.2 (World
Health Organization, Geneva, Switzerland).
Health status monitoring. Children were home-visited
every 2 weeks by a trained nurse. At each encounter, in-
formation regarding intercurrent episodes of acute illness and
use of antibiotics, as recalled by caregivers, was gathered.
Specimencollection.The studydesign included collection
of blood samples for the measurement of markers of mucosal
damage and systemic inflammation and a fecal sample for
microbiota composition at baseline and the end of follow-up.
Blood sampleswere collectedby venipuncture at the research
center, left to coagulate, and centrifuged to remove the serum
within 5 hours of blood collection. Stool samples for micro-
biome analysis were collected on the same day of blood
samples and conserved on ice for a maximum of 4 hours.
Serumand stool sampleswere then frozen in dry shippers and
sent to the reference laboratory where they were stored
at −70C until analysis.
Measurement of serum biomarkers. Serum-soluble CD14
(sCD14) was assessed using the human magnetic Luminex
screening assay and interleukin-1β (IL-1β), IL-6, and tumor ne-
crosis factor alpha (TNF-α) using the human magnetic Luminex
performance assay (both R&D Systems, Minneapolis, MN)
according to the manufacturer’s protocol. Lipopolysaccharide-
binding protein (LBP), intestinal fatty-acid–binding protein (I-
FABP), and zonulinweremeasured using commercially available
ELISAkits (Abnova, TaipeiCity, Taiwan;R&DSystems; and IDK®
Zonulin ELISA kit, Bensheim, Germany, respectively) according
to the manufacturer’s protocol.
Microbiomeanalysis.Microbial DNA extraction, 16S rRNA
gene amplification, and deep-sequencing. Bacterial genomic
DNA was extracted from human feces using the MoBio
PowerMag Microbiome DNA/RNA isolation kit (Carlsbad, CA)
following the manufacturer’s instructions, followed by ampli-
fication of the V4 regions of the 16S rRNA gene using in-
dividually barcoded universal primers containing linker
adapters for Illumina sequencing. Sequencing was performed
using a MiSeq system (Illumina Inc., San Diego, CA).
16S data analysis. Sequence processing and analysis were
performed using specific software for comparison and anal-
ysis of microbial communities (QIIME and mothur). Pair-end
reads of length 2 × 250 bp were demultiplexed and quality-
filtered according to the following parameters: a required
minimum average quality score of 35 over a 50-bp sliding
window, no homopolymer longer than 6 bp, no ambiguous
bases allowed, two primer mismatches allowed, and one
barcode mismatch allowed. Sequences were clustered and
binned into operational taxonomic units (OTUs) (based on
97% identity), and singleton reads were removed from the
dataset. The resulting OTU table was subsampled to the
smallest number of reads associated with any one sample.
Both theDNA extraction and 16S data analysis were carried
out at the Alkek Center for Metagenomics and Microbiome
Research, Baylor College of Medicine, Houston, Texas.
Statistical analysis. Continuous data distribution was
expressed in terms of medians and interquartile range. A Chi-
square test was used to compare categorical data. For each
biomarker, samples with levels below the lower limit of de-
tection were given an arbitrary value equal to one-half of the
value of the lowest measurable level. Similarly, samples with
levels above the upper limit of detection were set as twice the
value of the highest measured level. A Mann–Whitney U test
was used to compare the relative distribution of continuous
variables, unless otherwise specified. Spearman rank corre-
lation coefficient was used to measure the correlation be-
tween continuous variables. Cytokine concentration values
were log10-transformed for regression analysis.
The proportional change in serumbiomarkers, measured as
the difference between the baseline and end-of-follow-up
concentration divided by the baseline concentration, was
used as a measure of variation of the biomarkers over time.
Multiple logistic regression models were used to measure
the association between stunting and the change of each
biomarker during the follow-up period, after controlling for age
and LAZ score at enrollment.
For the microbiome analysis, we compared children who
became stunted at the endof the study (N= 16) with a restricted
group of children with an LAZ score above −1.5 at both enroll-
ment andendof follow-up (N=36), as thisclassificationallowed
for the best discrimination of groups (Supplemental Figure 2).
PairwiseBray–Curtisdiversity valueswerecalculatedbetween
each sample pair based on their overall microbiomeprofiles, and
groups of samples were compared using an unpaired two-tailed
t-test with unequal variance (data were normally distributed;
Shapiro–Wilk value of 0.96). The linear discriminant analysis ef-
fect size (LEfSe) method16 was used for differential taxa abun-
dance testing, usingdefault recommendedsettingsaccording to
the authors’ instructions, and an adjusted P £ 0.05 and an linear
discriminant analysis (LDA) effect size > 2 for significance. The
LEfSe algorithm performs class comparison tests, validates for
biological consistency, and is able to consider all taxonomic
levels for comparison simultaneously. Taxa were classified
according to the adjusted P-values for significance.
STATA version 12 (StataCorp., College Station, TX),
GraphPad Prism version 6 (La Jolla, CA), MS Excel 2016
(Microsoft Corp., Redmond, WA), and a Galaxy server (LEfSe)
were used for the analysis.
RESULTS
Participants. Seventy-eight children were enrolled in the
study. Three children were withdrawn from the study when
the parents moved away. The baseline characteristics of
the children are reported in Table 1. Individuals from the
two sites were similar in terms of age, gender distribution,
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anthropometric data, and diet habits, although children from
Moyobamba came from lower socioeconomic status.
Health status and growth trajectories. Every child en-
rolled in the study received a median of two visits per month.
Overall, the prevalence of acute infections during the 6-month
follow-up was low: we observed a median (IQR) of one (0–2)
episode of diarrhea (> 3 loose or watery stools in 24 hours) per
child in Urubamba and 0 (0–1) episode in Moyobamba (P =
0.05) and two1,2 episodes of upper respiratory tract infections
(nasal congestion, sore throat, or cough with or without fever
> 1 day) in Urubamba and 1 (0–2) inMoyobamba (P = 0.03); no
other episodes of acute illness or hospitalizations were re-
ported.Nochild in either site receivedmore thanone course of
antibiotics during the 6 months of follow-up. We did not ob-
serve differences in the incidence of acute infections between
children who became stunted and controls.
Sixty-one of 78 children (79%) presented a decline of their
LAZ scores during the study (Figure 1). By the end of the
follow-up, 16/75 (21%) childrenmet the criteria for definition of
stunting (LAZ < −2). These children were slightly older at en-
rollment (median age 10.5months versus 8months, P = 0.01),
had lower baselineWAZscores (−0.82 versus 0.1,P= 0.0002),
had lower baseline LAZ scores (−1.54 versus −0.42, P <
0.0001), and showed a larger decrease in LAZ score over time
than controls at the end of the follow-up (−1.11 versus −0.29,
P = 0.01) (Figures 1 and 2). Based on their birth records, the
birth weight and length of children who became stunted were
not significantly lower than those of children who did not be-
come stunted (Supplemental Table 1).
No differences were observed between stunted children
and controls in terms of household characteristics or dietary
patterns, including breastfeeding duration, average (DDS15),
daily consumption of animal food, or weekly household ex-
penditure for food supply (Supplemental Table 1). However,
given the small sample size, nonstatistically significant dif-
ferences should be interpreted with caution.
TABLE 1
Characteristics of the children at baseline, by research site
Urubamba (n = 38) Moyobamba (n = 40) P-value
Median age at enrollment (months) (25th, 75th) 9 (8, 10) 8.5 (7–12) 0.9†
Female, n (%) 15 (47) 17 (53) 0.8‡
Birth weight* (g) (25th, 75th) 3,346 (3160, 3532) 3,310 (3,000, 3,770) 0.9†
Length at birth* (cm) (25th, 75th) 49.5 (48, 51) 49.5 (48–50) 0.9†
Breastfeeding, any duration (months), n (%) 38 (100) 36 (90) 0.04‡
Length of exclusive breastfeeding (months) (25th, 75th) 6 (3, 6) 6 (3, 6) 0.9†
Age at introduction of solid food (months) (25th, 75th) 6 (6, 6) 6 (6, 6) 0.1†
Diet diversity score (25th, 75th) 4.5 (4, 5) 4 (3, 5) 0.9†
Consumption of animal foods at least 1/day, n (%) 30 (80) 26 (65) 0.2‡
Household characteristics
Maternal age (years) (25th, 75th) 26.5 (20–32) 26.5 (22–34) 0.6†
Level of maternal education, n (%)
None 0 (0) 1 (2.6)
Grammar school 1 (2.6) 15 (39.5)
High school 24 (63.1) 17 (44.7)
Technical school or university 13 (34.2) 5 (13.2) < 0.001‡
Median paternal age (years) (25th, 75th) 28.5 (25–38) 32.5 (30–40) 0.07
No. of people living in the house (25th, 75th) 4 (3–5) 5 (4–6) 0.05†
Households with indoor piped water provision, n (%) 38 (100) 19 (47.5) < 0.001‡
Households with a refrigerator, n (%) 19 (50) 26 (65) 0.1‡
Households connected to public sewage, n (%) 32 (84. 2) 17 (42.5) 0.001‡
Weekly average expense for food provision (nuevo sol) (25th, 75th) 140 (100, 150) 50 (40, 50) < 0.001†
* Information derived from child’s growth cards.
† Mann–Whitney U-test.
‡ Chi-square test.
FIGURE 1. Changes in anthropometricmeasuresduring follow-up. (A)Median changes inweight-for-age, length-for-age, andweight-for-lengthZ
scores during follow-up (75 children) and (B) median change in length-for-age Z score: stunted children (16 children) vs. non-stunted (59 children).
**P < 0.001, Mann–Whitney U-test.
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Three children were lost to follow-up between the 4th and
5th months of follow-up. Based on their last available mea-
surement, one had become stunted by the time he left the
study and the other two had shown a decrease in their LAZ
score.
Markers of enteropathy. Sixty-six of 78 children enrolled
had blood samples collected at baseline and the end of the
follow-up; the following results refer to this subset of partici-
pants. The remaining eight children had only one sample of
bloodcollected, either because theparents could not comeon
the days set for the blood draw or because they refused a
second venipuncture after the first attempt failed.
Intestinal fatty-acid–binding protein is a protein found in the
cytosol of intestinal epithelial cells and released into the
bloodstream on cell death.17 The I-FABP concentrations were
112 pg/mL to 14,959 pg/mL, values much higher than those
reported for healthy children in industrialized countries, 20 to
200 pg/mL.18 In our cohort, only 2/142 serum samples had a
concentration below 200 pg/mL.
Intestinal fatty-acid–binding protein baseline levels were
significantly higher in the group of children who later became
stunted (2252pg/mL versus 1,448 pg/mL,P=0.005), whereas
there was no difference between the stunted and control
subjects at the end of the study, as I-FABP concentration in-
creased in the latter group (Supplemental Table 2). The I-FABP
concentration change over time, however, was not statisti-
cally significant between stunted and control groups
(Figure 3A, Supplemental Figure 1).
Zonulin is aprotein secretedby viablegut epithelial cells and
is an important modulator of tight junctions.19 The concen-
tration of this marker in our cohort and its change over time
were not significantly different between stunted and control
children (Figure 3B, Supplemental Table 2).
Proinflammatory cytokines, sCD14, and LBP.
Interleukin-6, IL-1β, and TNF-α are mediators of the acute
phase response and have been implicated in growth delay of
children with chronic inflammatory diseases.20 Stunted and
control children had comparable values of serum IL-1β and IL-
6 at both time points (Figure 3C–E, Supplemental Table 2,
Supplemental Figure 1). Serum TNF-α showed a tendency to
increase more over time in children who became stunted
(proportional change 0.05 versus −0.15, P = 0.10), although
the result was statistically significant onlywhenwe conducted
the analysis using stricter criteria for controls (only children
who had an LAZ score > 1.5 both at enrollment and closure of
the study; Supplemental Figure 1).
SolubleCD14,which is shedbymonocytes after stimulation
by bacterial lipopolysaccharide (LPS), augmentsmacrophage
and neutrophil response to endotoxin. The serum concen-
tration of this marker is elevated in patients with enteropathy
and endotoxemia.21–23 Stunted children and controls had
similar levels of sCD14 at baseline, but by the end of the study
stunted children had significantly higher concentrations (me-
dian 2.01 × 106 pg/mL versus 1.78 × 106 pg/mL, P < 0.01;
Figure 3F, Supplemental Table 2).
Lipopolysaccharide-binding protein is a type-1 acute phase
protein involved in the systemic response to LPS.24
Lipopolysaccharide-binding protein levels were similar be-
tween stunted children and controls at baseline and showed a
tendency to increase among stunted children, although the
change was not statistically significant (0.46 versus −0.14, P =
0.07; Figure 3G, Supplemental Table 2, Supplemental
Figure 1). The change in concentrations of sCD14 and LBP
was strongly correlated (r = 0.76, P < 0.0001; Figure 3H).
Associations between linear growth and biomarkers.
Among stunted children, the baseline log-transformed con-
centration of I-FABP was strongly and inversely correlated
with change in LAZ scores over the following months
(r = −0.78, P < 0.01; Figure 4A). Conversely, among controls,
the baseline log-transformed concentration of I-FABP was
positively correlated with the change in LAZ scores (r = 0.67,
P = 0.04; Figure 4B). Among stunted children, the log-
transformed concentration of I-FABP at the end of the
follow-up showed amodest inverse correlationwith change in
LAZ scores, but this was only a statistical trend (Figure 4C).
There was no correlation between the log-transformed con-
centration of I-FABP at the end of the follow-up and change in
LAZ scores in the control children (Figure 4D).
A binary logistic analysis showed that the odd of becoming
stuntedwassignificantly associatedwitholder ageat enrollment
(OR 1.4, P = 0.03), a lower length-for-age Z score (LZA) at en-
rollment (OR 0.08, P = 0.002), and an increase in sCD14 con-
centration over time (OR 9.7, P = 0.01). No other statistically
significant associationswere noted between stunting at the end
of the follow-up and change in markers, although there was a
trend toward increasedoddofbecomingstuntedwith increasing
levels of LBP (OR5.4,P=0.08). In amultiple logistic analysis, the
oddsofbecomingstuntedwere still significantly associatedwith
the increase in sCD14 level over time even after controlling for
age and HAZ score at enrollment (OR 8.7, P = 0.03).
Fecal microbiome. Seventy-five children had two sets of
stool samples available for microbiome studies, but, as de-
scribed in the Methods section, we only compared the fecal
microbiome of the children stunted at the end of the follow-up
(N = 16) with themicrobiome of childrenwhose LAZ scorewas
above−1.5 throughout the study (N = 36). For this analysis, we
compared children whomet the criteria for stunting at the end
of the follow-up (LAZ < −2) with children with an LAZ score
greater than −1.5 at both enrollment and end of the follow-up,
as this classification allowed for thebest discriminationof data
(Supplemental Figure 2).
The alpha diversity (within-sample diversity) of the fecal
microbiota, measured as the Shannon index, increased with
FIGURE 2. Monthly changes in length-for-age Z (LAZ) score, stun-
ted children (N = 16) vs. non-stunted (N = 59) children. The children
who developed stunting at the end of the follow-up had a lower LAZ
score at enrollment and at each time point during the follow-up (each
point indicates the median value per group; error bars indicate 95%
CI). At the end of the follow-up, themedian decrease in LAZ scorewas
−1.1 for children meeting the criteria for stunting vs. −0.29 for non-
stunted children (P = 0.01).
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age in both cases and control. We did not observe differences
based on gender, site of residence (highlands versus jungle),
or nutritional status (data not shown), but the study was not
powered to show differences between these subgroups.
With regard to beta diversity (between-sample diversity),
Bray–Curtis analysis (Figure 5) showed that 1) the average
beta diversity of intestinal microbiota was significantly differ-
ent between children developing stunting and controls at both
baseline and end of follow-up (P = 0.047 and P = 0.0015,
respectively); 2) control children had a more heterogenous
microbiota composition at enrollment, but heterogeneity de-
creased over time (P = 0.021); 3) children who developed
stunting had a less heterogenous composition at baseline, but
there was a change toward more diversity (P = 0.0043) at the
end of follow-up (Figure 5).
The relative abundance of bacterial taxa in the gutmicrobial
communities was assessed using the previously described
LEfSe method. As expected, during the follow-up, we
observed a reduction of taxa belonging to the phylum
Actinobacteria (Bifidobacteriaceae) and Proteobacteria
(Enterobacteriaceae) and an increase in taxa belonging to
Firmicutes (members of Lachnospiraceae family, such as
Roseburia, Blautia, and Pseudobutyrivibrio, and Rumino-
coccaceae family) and Bacteroidetes in both groups. How-
ever, when we compared the fecal microbiome of stunted
children versus controls, we observed some differences. The
relative abundance of some specific genera belonging to the
families of Ruminococcaceae (Ruminococcus 1 and 2) and
Coriobacteriaceae (Collinsella) increased over time in the
children who became stunted but not in children with normal
growth. Conversely, in these children, there was a decrease in
the relative abundance of one genus of Enterobacteriaceae
(Providencia) which was not observed in the microbiome of
controls (Table 2 and Supplemental Figure 3).
DISCUSSION
In this pilot study conducted among Peruvian infants living
in rural regions, we found that 1) during a 6-month observation
period, 79% of the children showed a decrease in their LAZ
FIGURE 3. Proportional changes in blood levels of seven serum biomarkers during the 6-month follow-up, stunted children (N = 16) vs. non-
stunted (N=59) children.GraphsA–F reportmedianswith the 25th–75th percentile (Mann–WhitneyU-test). GraphH shows the correlation between
changes in sCD14 and LBP over time (Spearman rank correlation).
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score and 21% developed clinical stunting; 2) almost all par-
ticipants had higher than expected levels of I-FABP; 3) an
increase in sCD14 was associated with becoming stunted;
and 4) the fecal microbiome of stunting children followed a
different trajectory compared with controls.
This observational study confirms that stunted growth re-
mains a widespread problem, even in countries like Peru
where acute malnutrition is becoming rare. If we consider that
stunting may be the most evident feature of a complex syn-
drome associated with long-lasting metabolic, immunologi-
cal, and cognitive changes, the public health relevance of this
phenomenon appears evident.
In our cohort, we did not observe differences in household
wealth, diet, or frequency of acute infections between stunted
and control children, but we did note interesting differences in
the serum concentrations of markers of intestinal cell turnover
and innate immune system activation.
In two repeated occasions, the young infants living in Uru-
bamba and Moyobamba showed levels of serum I-FABP well
above the reference values.22,25,26 Another study conducted
in Zimbabwe on a birth cohort of children living in impov-
erished conditions reported comparable data.6 Intestinal
fatty-acid–binding protein is almost solely expressed in the
enterocytes of the small intestine and it is more concentrated
in the cells at the top of the villi.17 Studies conducted in pa-
tients with celiac disease (a disorder sharing many of the
histological and functional features of EED) showed that this
marker correlates with disease activity and the extent of villi
flattening.18,26 In the few infants included in celiac disease
studies, serum I-FABP levels were extremely high at the time
of diagnosis but rapidly normalized after gluten removal,
probably reflectingnot only theexquisite vulnerability of a fast-
growing mucosa to external insults but also the potential for
rapid healing.
The relationship between I-FABP levels and linear growth in
cases andcontrolswascontradictory butmaybeexplainedby
considering this as a marker of intestinal functional reserve
rather than just enterocyte death.27 Children living in low-
resource, unhygienic settings are continuously exposed to a
vast array of intestinal pathogens,28–31 and it is conceivable
that the increased levels of I-FABP represent the accelerated
turnover of a rapidly growing mucosa subjected to ongoing
damage and forced to continuously regenerate itself. In the
presence of a reduced availability of nutrients however, the
rate of mucosal damage may exceed the healing potential of
the host, leading to a vicious cycle of reduction of the enter-
ocyte mass, further compromise of nutrient harvesting,
damage of the intestinal barrier integrity, innate immune acti-
vation, and growth delay. It is tempting to hypothesize that
children who developed stunting in our study were already at
FIGURE 4. Correlation between intestinal fatty-acid–binding protein (I-FABP) levels and change in length-for-age Z scores (LAZ) in stunted
children (16) vs. non-stunted children (59). The concentration of serum I-FABPwas inversely correlatedwith changes in LAZ scores among stunted
children, whereas it seemed to have a weak positive correlation with LAZ score change in children who did not become stunted. r = Spearman
correlation coefficient.
FIGURE 5. Bray–Curtis diversity comparisons among fecal micro-
biome samples collected at baseline and end of follow-up, stunted
children vs. non-stunted children.P-values are calculatedusing t-test.
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the limit of their functional reserve at enrollment and, over the
following,months suffered from aprogressive loss ofmucosal
surface, which eventually resulted in clinical signs of stunting.
Consistent with other studies,5,6,10 we found stigmata of in-
nate immune activation in children who became clinically
stunted. Both membrane-bound and sCD14 accelerate LPS–
LBPcomplex recognition by Toll-like receptor-4onmonocytes,
macrophages, and dendritic cells.24 Our sCD14 and LBP
findings suggest increased microbial translocation across
the intestinal mucosa and increased LPS-induced immune
activation.21,22 Our findingsmay indeed signify that the origin of
immune activation in stunted children is a sustained low-grade
microbial translocation through an exhausted intestinal mu-
cosa. They can also partially explain the increased risk of death
due to sepsis, tuberculosis, meningitis, or nonspecific febrile
episodes in children with severe stunting32 because chronic,
low-grade exposure to bacterial products may induce a status
of tolerance,whereby immunecellsbecomerelativelyanergic to
endotoxin stimulation,33 or priming, whereby immune cells ex-
hibit an exaggerated inflammatory response.34 In either case,
the abnormal inflammatory response will make the host less
likely to survive to a severe infection.
It is increasingly recognized that commensal flora plays a
critical role in host metabolic and immune homeostasis. The
intestinal microbiota participates in nutrient harvesting and in-
teracts with the host epithelial and immune cells tomaintain the
equilibrium between tolerance toward exogenous molecules
andpreparednessagainst pathogen invasion. This symbiosis is
particularly fascinating in the early stages of life, as the pre-
dictable, ordered assembly of the gut microbiome and its
functional capacity appear to be essential for the healthy de-
velopment of the child.35–37 Many factors, including genetics,
mode of delivery, age, diet, use of antibiotics, and themother’s
microbiome, can affect the infant gutmicrobiota composition.
TABLE 2
Gut microbiome analysis: changes in the relative abundance of selected taxa
Phylum Class Order Family Genus
Not stunted Stunted
LDA P-value LDA P-value
Taxa with relative abundance increasing over time in stunted children but not in non-stunted
Firmicutes – – – – 4.61 0.110 4.98 0.007
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 1 2.22 0.088 2.85 0.008
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 2 2.59 0.615 3.05 0.025
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcaceae UCG 014 2.94 0.185 3.42 0.043
Firmicutes Clostridia Clostridiales Lachnospiraceae – 4.46 0.097 4.74 0.037
Firmicutes Clostridia Clostridiales Lachnospiraceae Uncultured 2.12 0.068 2.64 0.012
Firmicutes Clostridia Clostridiales Clostridiaceae 1 3.73 0.364 3.85 0.031
Firmicutes Clostridia Clostridiales Clostridiaceae 1 Clostridium sensu stricto 1 3.20 0.526 3.60 0.043
Actinobacteria Coriobacteria Coriobacteriales Coriobacteriaceae Collinsella 2.39 0.693 2.59 0.035
Taxa with relative abundance increasing over time in both stunted and non-stunted children
Firmicutes Clostridia – – – 4.78 0.018 4.96 0.013
Firmicutes Clostridia Clostridiales – – 4.78 0.018 4.96 0.013
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnospiraceae UCG 004 2.14 0.008 2.78 0.002
Firmicutes Clostridia Clostridiales Lachnospiraceae Roseburia 3.50 0.010 3.83 0.007
Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 3.25 0.018 3.60 0.010
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnospiraceae NK4A136
group
3.44 0.004 3.91 0.017
Firmicutes Clostridia Clostridiales Lachnospiraceae Fusicatenibacter 3.53 0.013 3.66 0.023
Firmicutes Clostridia Clostridiales Lachnospiraceae Pseudobutyrivibrio 4.17 0.024 4.04 0.032
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnospiraceae UCG 010 2.55 0.005 2.61 0.048
Firmicutes Clostridia Clostridiales Christensenellaceae – 3.25 0.001 2.62 0.025
Firmicutes Clostridia Clostridiales Christensenellaceae Christensenellaceae R-7
group
3.24 0.007 2.61 0.025
Firmicutes Clostridia Clostridiales Family XIII – 2.01 0.031 1.99 0.028
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcaceae UCG 002 3.61 0.008 3.64 0.047
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Butyricimonas 2.40 0.021 2.32 0.036
Taxa with relative abundance decreasing in stunted children but not in non-stunted children
Proteobacteria Gammaproteo-
bacteria
Enterobacteriales Enterobacteriaceae Providencia 3.07 0.191 2.88 0.036
Taxa with relative abundance decreasing over time in both stunted and non-stunted children
Actinobacteria – – – 4.57 0.004 4.56 0.003
Actinobacteria Actinobacteria – – 4.57 0.004 4.53 0.004
Actinobacteria Actinobacteria Bifidobacteriales – – 4.56 0.005 4.53 0.004
Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae – 4.56 0.005 4.53 0.004
Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium 4.56 0.005 4.53 0.004
Proteobacteria Gammaproteo-
bacteria
– – – 4.70 0.013 4.71 0.048
Proteobacteria Gammaproteo-
bacteria
Enterobacteriales – 4.64 0.027 4.79 0.013
Proteobacteria Gammaproteo-
bacteria
Enterobacteriales Enterobacteriaceae – 4.64 0.027 4.79 0.013
Proteobacteria Gammaproteo-
bacteria
Enterobacteriales Enterobacteriaceae Escherichia–Shigella 4.59 0.028 4.78 0.014
For the purposeof this analysis, only non-stuntedchildren having an LAZ³−1.5 at the endof the follow-up (N=36)were usedas comparison vs. stuntedchildren (defined as childrenwith anLAZ£
−2 at the end of the follow-up) (N = 16) as this classification allowed for the best discrimination of data.
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However, the interindividual diversities (β-diversity) de-
crease with age, and after the first 3 years of life, there is a
remarkable consistency among healthy individuals.35,37
Aberrant microbiota composition has been associated with
numerous diseases in childhood and later in life.38,39
The analysis of the fecal microbiota evolution of these
children over the 6-month follow-up showed some expected
changes in both cases and controls. First, the within-sample
diversity of the samples increased with age, reflecting the
acquisition of new bacterial strains from the environment.
Second, some of the changes in the bacterial communities
followed the predictable age-dependent pattern: Enter-
obacteriaceae and Bifidobacteriaceae, typically predominant
in the intestine of very young infants, decreased over time,
whereas members of the Lachnospiraceae expanded.35,36,39
Bacteria belonging to this family often produce short-chain
fatty acids that regulate host immunity through the induction
of regulatory T cells and help maintain enterocyte health and
have been considered markers of a healthy microbiota.40,41
Interestingly, despite the limited sample size, we were also
able to appreciate differences between the gut microbiota of
stunted and non-stunted children. First, differences in fecal
microbiota composition between cases and controls were
already present at baseline, before any child had developed
signs of clinical stunting, and persisted throughout the study
(Figure 5), possibly signifying that the intestinal microbiome is
a driver, or shares an upstream mediator, with stunting. If
changes in the gut microbiota result in decreased energy
harvesting from food, interventions aimed at restoring a
healthy commensal floramaybe just as important asproviding
an age-appropriate diet to cure stunting. An arrest of the
maturation of intestinal microbiome has indeed already been
described in children with severe acute malnutrition.42,43
Previous studies comparing the gut microbiota of healthy
versus malnourished children have often found dissimilarities
between the groups but the bacteria identified as discrimi-
nant are not consistent, probably due to differences in age,
geography, type of malnutrition, and sample-processing
techniques.42–45 Inferring the potential significance of such
differences is arduous: the human microbiome possesses an
extraordinary functional redundancy, and the true significance
of changes in the relative abundance of some species needs
to be investigated with sophisticated metagenomic analyses
that were beyond the scope of this pilot study.
Our study has other limitations1: The sample size is small
and probably explains some of the nonstatistically significant
findings.2 Our childrenwere of slightly different ages; although
the differenceswere in terms ofmonths, the tremendous pace
of changes in the physiology andmicrobiota characteristics of
this period of life makes them remarkable and potentially
confounds some of the results.3 Themicrobiome analysis was
performed on fecal samples which are not necessarily repre-
sentative of the bacterial communities populating different
segments of the intestine.
In summary, we found that the clinical onset of stunting is
preceded by the appearance of markers of accelerated mu-
cosal turnover, systemic inflammation, and changes in the gut
microbiota. Future studies aimed at characterizing the pro-
gressive functional maturation of the intestinal mucosa and
microbiome and their cross-talk with the developing immune
system in the early stages of lifemay offer new approaches for
the prevention and cure of the stunting syndrome.
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